AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comOCT 22 min read$VICR

Analysts Offer Insights on Technology Companies: Vicor (VICR) and Braze (BRZE)

Analysts from Needham reiterated Buy ratings on Vicor (VICR) and Braze (BRZE). Vicor's price target set at $350, with a consensus target of $362.50. Braze's price target set at $50, with a consensus target of $36.94. Both stocks have a Strong Buy consensus.

Original reporting
theglobeandmail.com
Published Oct 2, 2026, 11:13 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 12:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Analysts Offer Insights on Technology Companies: Vicor (VICR) and Braze (BRZE) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$VICRBullishMed
01

Why it matters

Both upgrades provide new price targets that suggest significant upside, potentially prompting buying interest.

02

Market read

New analyst ratings with higher price targets can drive short‑term buying pressure in the covered stocks.

03

What to watch

Execution risk and broader market volatility could mute the impact of the upgrades.

Relevance 6/10Novelty 5/10Timing: today

Background

The article aggregates two fresh analyst upgrades for Vicor and Braze, both small‑cap tech companies.

Company-level read

Ticker impact

$VICRBullishHigh confidence
Context

Needham analyst Quinn Bolton reiterated a Buy rating on Vicor and set a $350 price target, new today.

Expected impact

likely upward pressure as investors price in the new $350 target

Evidence & confidence

Buy rating and a 21% upside target are fresh and actionable.

$BRZEBullishHigh confidence
Context

Needham analyst Scott Berg assigned a Buy rating to Braze with a $50 price target, new today.

Expected impact

likely upward pressure as the market absorbs the new $50 target

Evidence & confidence

Buy rating and a 100% upside target constitute fresh, material information.

Market effects

Sector

Positive analyst sentiment may lift other small‑cap technology stocks.

Regional

U.S. tech sector may see modest gains.

Global

Limited to investors tracking U.S. growth tech names.

Counterpoint

What could challenge this read

If the price targets are overly optimistic, the stocks could face short‑term profit taking.

Key entities

  • Analyst
    Quinn Bolton

    Needham analyst who upgraded Vicor.

  • Analyst
    Scott Berg

    Needham analyst who upgraded Braze.

Read at source← All news

Related articles

OCT 6
$VICRMed

Vicor (VICR) Has the AI Power Opportunity. Can It Actually Scale?

Vicor Corporation (VICR) is gaining attention for its role in AI infrastructure, with its power systems crucial for GPUs and networking chips. The stock's forward P/E has reached 47.17x, and its one-year backlog is $379.7 million, up 26%. Management expects over $600 million in revenue by 2026 and highlights its licensing business as a growth driver. However, the company may face capacity constraints as it plans to build additional fabrication facilities.

finance.yahoo.com2 min
OCT 1
$ACNMed

Stocks making the biggest moves midday: Accenture, Synopsys, United Therapeutics, Vicor and more

Accenture rose 18% after Q4 revenue of $18.7B beat estimates. McCormick's Q3 results topped expectations but shares fell 2% amid Unilever's acquisition. McKesson gained 4% on reaffirmed guidance and a CVS Health partnership. United Therapeutics climbed 6% after a court ruling, while Liquidia dropped 15%. Constellation Energy gained 3% on a 20-year Amazon deal. Synopsys jumped 8% with 2027 revenue targets. Sigma Lithium slid 16% after halting production.

cnbc.com3 min
OCT 1
$ACNHighAI 8/10

Interesting stocks today as October month starts

Accenture (ACN) surged 23% after reporting Q4 revenue of $18.68B, exceeding expectations. Micron (MU) saw minimal gains despite strong earnings. Synopsys (SNPS) rose 9.7% on AI partnerships and revenue growth outlook. Liquidia (LQDA) fell further after a patent ruling. Investors reacted to earnings and catalysts.

investinglive.com2 min